Browsing by Author "Rodriguez, A"

Now showing 1 - 5 of 5

Genomic Landscape in Prostate Cancer in a Latin American Population
(Lippincott Williams and Wilkins, 2024) Angel, M; Freile, B; Rodriguez, A; Cayol, F; Manneh, Kopp, R; Rioja, P; Soule, T; Losco, F; Bernal, Vaca, L; Penaloza, JM; Zapata, Muñoz, ML; Neciosup, SP; Sanchez, RR; Passarella, C; Guerreño, E; Farelluk, D; Maturana, Leiva, E; Zarba, M; Bourlon, MT; Mora, Pineda, M; Sade, JP
PURPOSEThis study aims to describe genomic characteristics of patients with metastatic prostate cancer (mPC).PATIENTS AND METHODSThis study is a retrospective, multicenter cohort study of patients with mPC and reports on genomic testing. Patients were included from 12 academic centers in five countries.RESULTSA total of 349 patients with PC were included in this study. Most patients (209, 59.9%) were de novo metastatic. Genomic analysis was performed in 233 (66.6%) patients in the metastatic castration-resistant prostate cancer (mCRPC) setting, and only 115 (32.8%) patients had a tumor evaluation in the metastatic hormone sensitive prostate cancer scenario. The evaluation of somatic and/or germline mutations was performed through multigene panel analyses in 290 (83.09%) patients, and next-generation sequencing of BRCA1 and BRCA2 genes was performed in 59 (16.91%) patients. Analyzing the mCRPC subgroup, with a median follow-up of 15.6 months (IQR, 14-19.06), the median progression-free survival (PFS) was not reached (NR) and the PFS at 16 months was 58.7% (95% CI, 50.8 to 67.8). When comparing patients with BRCA mutations with those who are not BRCA-mutated in the mCRPC scenario, the median PFS was NR (95% CI, 14 to NR) and 26.3 months (95% CI, 16.7 to 36.5; P =.2), respectively. Two of six patients with BRCA mutations were treated with targeted therapies (poly-ADP-ribose polymerase inhibitors).CONCLUSIONOur study, to the best of our knowledge, represents one of the larger data sets for somatic testing in patients with PC in Latin America (LATAM). It adds valuable information to the growing body of knowledge about the genomic landscape of advanced PC in real-world daily practice scenarios in LATAM countries, which are not always well-represented in large-scale randomized clinical trials. © 2024 by American Society of Clinical Oncology.
SELNET clinical practice guidelines for bone sarcoma
(Elsevier Ireland Ltd, 2022) Blay, JY; Palmerini, E; Bollard, J; Aguiar, S; Angel, M; Araya, B; Badilla, R; Bernabeu, D; Campos, F; Carvajal-Montoya, A; Casavilca-Zambrano, S; Castro-Oliden, Víctor; Chacón, M; Clara-Altamirano, MA; Collini, P; Correa-Genoroso, R; Costa, FD; Cuellar, M; dei Tos, AP; Dominguez-Malagon, HR; Donati, DM; Dufresne, A; Eriksson, M; Farias-Loza M; Frezza, AM; Frisoni, T; Garcia-Ortega, DY; Gerderblom, H; Gouin, F; Gómez-Mateo, MC; Gronchi, A; Haro, J; Hindi, N; Huanca, L; Jimenez, N; Karanian, M; Kasper, B; Lopes, A; Lopes David, BB; Lopez-Pousa, A; Lutter, G; Maki, RG; Martinez-Said, H; Martinez-Tlahuel, JL; Mello, CA; Morales-Pérez, JM; Moura, DS; Nakagawa, SA; Nascimento, AG; Ortiz-Cruz, EJ; Patel, S; Pfluger, Y; Provenzano, S; Righi, A; Rodriguez, A; Santos, TG; Scotlandi, K; Soulé, T; Stacchiotti, S; Valverde, CM; Waisberg, F; Zamora-Estrada, E; Martin-Broto, J
Bone sarcoma are infrequent diseases, representing < 0.2% of all adult neoplasms. A multidisciplinary management within reference centers for sarcoma, with discussion of the diagnostic and therapeutic strategies within an expert multidisciplinary tumour board, is essential for these patients, given its heterogeneity and low frequency. This approach leads to an improvement in patient's outcome, as demonstrated in several studies. The Sarcoma European Latin-American Network (SELNET), aims to improve clinical outcome in sarcoma care, with a special focus in Latin-American countries. These Clinical Practice Guidelines (CPG) have been developed and agreed by a multidisciplinary expert group (including medical and radiation oncologist, surgical oncologist, orthopaedic surgeons, radiologist, pathologist, molecular biologist and representatives of patients advocacy groups) of the SELNET consortium, and are conceived to provide the standard approach to diagnosis, treatment and follow-up of bone sarcoma patients in the Latin-American context. © 2022 The Authors
SELNET clinical practice guidelines for bone sarcoma
(Elsevier Ireland Ltd, 2022) Blay, JY; Palmerini, E; Bollard, J; Aguiar, S; Angel, M; Araya, B; Badilla, R; Bernabeu, D; Campos, F; Chs, CS; Carvajal Montoya, A; Casavilca-Zambrano, S; Castro-Oliden, V; Chacón, M; Clara-Altamirano, MA; Collini, P; Correa Genoroso, R; Costa, FD; Cuellar, M; Dei Tos, AP; Dominguez Malagon, HR; Donati, DM; Dufresne, A; Eriksson, M; Farias-Loza, M; Frezza, AM; Frisoni, T; Garcia-Ortega, DY; Gerderblom, H; Gouin, F; Gómez-Mateo, MC; Gronchi, A; Haro, J; Hindi, N; Huanca, L; Jimenez, N; Karanian, M; Kasper, B; Lopes, A; Lopes David, BB; Lopez-Pousa, A; Lutter, G; Maki, RG; Martinez-Said, H; Martinez-Tlahuel, JL; Mello, CA; Morales Pérez, JM; Moura, DS; Nakagawa, SA; Nascimento, AG; Ortiz-Cruz, EJ; Patel, S; Pfluger, Y; Provenzano, S; Righi, A; Rodriguez, A; Santos, TG; Scotlandi, K; Mlg S, Soulé T; Stacchiotti, S; Valverde, CM; Waisberg, F; Zamora Estrada, E; Martin-Broto, J
Bone sarcoma are infrequent diseases, representing < 0.2% of all adult neoplasms. A multidisciplinary management within reference centers for sarcoma, with discussion of the diagnostic and therapeutic strategies within an expert multidisciplinary tumour board, is essential for these patients, given its heterogeneity and low frequency. This approach leads to an improvement in patient's outcome, as demonstrated in several studies. The Sarcoma European Latin-American Network (SELNET), aims to improve clinical outcome in sarcoma care, with a special focus in Latin-American countries. These Clinical Practice Guidelines (CPG) have been developed and agreed by a multidisciplinary expert group (including medical and radiation oncologist, surgical oncologist, orthopaedic surgeons, radiologist, pathologist, molecular biologist and representatives of patients advocacy groups) of the SELNET consortium, and are conceived to provide the standard approach to diagnosis, treatment and follow-up of bone sarcoma patients in the Latin-American context.
SELNET clinical practice guidelines for soft tissue sarcoma and GIST
(W.B. Saunders Ltd, 2022) Blay, JY; Hindi, N; Bollard, J; Aguiar, S Jr; Angel, M; Araya, B; Badilla, R; Bernabeu, D; Campos, F; Caro-Sánchez, CHS; Carvajal, B; Carvajal Montoya, A; Casavilca-Zambrano, S; Castro-Oliden, V; Chacón, M; Clara, M; Collini, P; Correa Genoroso, R; Costa, FD; Cuellar, M; Dei Tos, AP; Dominguez Malagon, HR; Donati, D; Dufresne, A; Eriksson, M; Farias-Loza, M; Fernandez, P; Frezza, AM; Frisoni, T; Garcia-Ortega, DY; Gelderblom, H; Gouin, F; Gómez-Mateo, MC; Gronchi, A; Haro, J; Huanca, L; Jimenez, N; Karanian, M; Kasper, B; Lopes David, BB; Lopez-Pousa, A; Lutter, G; Martinez-Said, H; Martinez-Tlahuel, J; Mello, CA; Morales Pérez, JM; Moura David, S; Nascimento, AG; Ortiz-Cruz, EJ; Palmerini, E; Patel, S; Pfluger, Y; Provenzano, S; Righi, A; Rodriguez, A; Salas, R; Santos, TTG; Scotlandi, K; Soule, T; Stacchiotti, S; Valverde, C; Waisberg, F; Zamora Estrada, E; Martin-Broto, J
Soft tissue sarcoma (STS) and gastrointestinal tumors (GIST) encompass > 80 different histologic subtypes. Clinical practice guidelines for STS and GIST still lack in Latin-American countries. Tailored clinical guidelines are instrumental to improve outcome in sarcoma patients in LatinAmerican countries. This is the first review establishing STS and GIST guidelines for the purpose of LatinAmerican clinical practices to our knowledge.
SELNET clinical practice guidelines for soft tissue sarcoma and GIST
(W.B. Saunders Ltd, 2022) Blay, JY; Hindi, N; Bollard, J; Aguiar, S; Angel, M; Araya, B; Badilla, R; Bernabeu, D; Campos, F; Caro-Sánchez, CHS; Carvajal, B; Carvajal Montoya, A; Casavilca-Zambrano, S; Castro-Oliden V; Chacón, M; Clara, M; Collini, P; Correa-Genoroso, R; Costa, FD; Cuellar, M; dei Tos, AP; Dominguez Malagon, HR; Donati, A; Dufresne, A; Eriksson, M; Farias-Loza, M; Fernandez, P; Frezza, AM; Frisoni, T; Garcia-Ortega, DY; Gelderblom, H; Gouin, F; Gómez-Mateo, MC; Gronchi, A; Haro, J; Huanca, L; Jimenez, N; Karanian, M; Kasper, B; Lopes David, BB; Lopez-Pousa, A; Lutter, G|Martinez-Said, H; Martinez-Tlahuel, J; Mello, CA; Morales-Pérez, JM; Moura-David, S; Nascimento, AG; Ortiz-Cruz, EJ; Palmerini, E; Patel, S; Pfluger, Y; Provenzano, S; Righi, A; Rodriguez, A; Salas, R; Santos, TTG; Scotlandi, K; Soule, T; Stacchiotti, S; Valverde, C; Waisberg, F; Zamora Estrada, E; Martin-Broto, J
Soft tissue sarcoma (STS) is a heterogeneous group of neoplasms, encompassing > 80 different histologic subtypes. Approximately three quarter of sarcoma arise from soft-tissue, about 15% are gastrointestinal stromal tumours (GISTs) and bone sarcoma represent the remaining 10%. The current guidelines will focus on soft-tissue and GIST, excluding Kaposi sarcoma and non-pleomorphic rhabdomyosarcoma. Bone sarcomas are covered in a different paper.